Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Metabolism Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BCAT1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | BCAT1 Recombinant Protein (WT & Mutant) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. |
View BCAT1 Products |
| Mutant Controls | BCAT1 K222A (Catalytic Dead) Mutant Protein Site-directed mutagenesis verified by sequencing, for negative control assays. |
View BCAT1 Products |
| Gene Delivery | BCAT1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. HEK293 packaging system. |
View BCAT1 Products |
| Benchmark Ab | Anti-BCAT1 Recombinant Antibody Research-grade detection control for target engagement, Western blot, and IHC. |
View BCAT1 Products |
| Validator | BCAT1 siRNA Set For genetic knockdown and assay specificity verification. |
View BCAT1 Products |
| Related Target: BCAT2 | BCAT2 (Mitochondrial Isoform) Essential paralog for isoform selectivity counter-screening and off-target profiling. |
View BCAT2 Products |
| Related Target: BCKDK | BCKDK (Branched-Chain Ketoacid Dehydrogenase Kinase) Downstream BCAA pathway regulator for combination therapy logic. |
View BCKDK Products |
| Related Target: IDH1 | IDH1 (Isocitrate Dehydrogenase 1) Synthetic lethal partner in AML metabolism; highly expressed in IDH-wildtype gliomas. |
View IDH1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (BCAT1 vs. BCAT2) | Human BCAT1 and BCAT2 recombinant proteins available as a matched pair; >95% purity; sequence verified. |
| Enzymatic Inhibition & Binding Kinetics | WT and active-site mutant proteins expressed in HEK293 for native folding; endotoxin controlled for sensitive cell assays. |
| Catalytic Mechanism Validation | Catalytic-dead mutant (K222A) available as rigorous negative control for transamination assays. |
| Cell-Based Target Engagement | High-titer lentivirus particles for stable BCAT1-overexpressing lines; compatible with CETSA and proliferation rescue assays. |
| Assay Specificity & False Positives | Validated siRNA included for genetic knockdown confirmation; eliminates off-target compound noise. |
Live BCAT1 R&D Tracker
Global Clinical Landscape & Future Outlook
BCAT1 has emerged as a critical node in tumor branched-chain amino acid (BCAA) metabolism. Elevated expression correlates with aggressive disease in glioblastoma (GBM), acute myeloid leukemia (AML), and renal cell carcinoma. The current therapeutic landscape is dominated by early-stage small-molecule inhibitor programs and genetic validation studies. As first-generation inhibitors advance from hit-to-lead optimization, the next wave of R&D is targeting isoform-selective allostery, blood-brain barrier penetrance for CNS malignancies, and synthetic-lethal combinations with standard-of-care chemotherapy. Critical differentiation factors include selective BCAT1 inhibition over mitochondrial BCAT2 to avoid systemic BCAA metabolism toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small-Molecule Inhibitor | Emerging biotech & academic consortia | GBM, AML, Renal Cell Carcinoma | Isoform-selectivity panel: BCAT1 vs. BCAT2 recombinant proteins (>95% purity) for IC50 profiling |
| Genetic Knockdown (siRNA/CRISPR) | Research institutions | Metabolic cancers | Knockdown validation using TarMart siRNA sets and lentivirus-based stable lines |
| PROTAC / Targeted Degradation | Early discovery biotech | Solid tumors | Cell-based degradation assays requiring full-length BCAT1 lentivirus stable cell lines |
| Allosteric Modulators | Emerging academic programs | Metabolic disorders | Conformational binding assays (need full-length native proteins) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Selectivity (BCAT1 vs. BCAT2): BCAT2 is essential for normal BCAA metabolism in heart and skeletal muscle. Best-in-class drugs must achieve >100-fold selectivity to avoid systemic toxicity. TarMart provides matched high-purity BCAT1 and BCAT2 proteins for parallel IC50 profiling.
- Enzymatic Mechanism: BCAT1 is PLP-dependent with a two-substrate mechanism. Inhibitors can be PLP-competitive, substrate-competitive, or allosteric. The K222A catalytic-dead mutant serves as a negative control to distinguish mechanism-based inhibition from simple binding.
- Cellular Target Engagement: Intracellular targets require membrane-permeable compounds. Lentivirus-based stable cell lines enable CETSA and proliferation rescue assays to verify target occupancy.
- CNS Penetration: For GBM, drugs must cross the blood-brain barrier. BCAT1 lentivirus can be used to build BBB transcytosis models.
Recommended Screening Assays
| Differentiation Dimension | Recommended Assay | TarMart Support |
|---|---|---|
| Isoform Selectivity | Parallel BCAT1/BCAT2 enzymatic inhibition (spectrophotometric/MS-based) | Matched human BCAT1 & BCAT2 recombinant proteins, >95% purity, sequence verified |
| Binding Kinetics | SPR / BLI | High-purity BCAT1 (HEK293 expressed, endotoxin <1 EU/µg) for stable chip immobilization |
| Cellular Target Engagement | Cellular Thermal Shift Assay (CETSA) / Reporter Assay | Pre-packaged BCAT1 overexpression lentivirus for stable cell line construction |
| Specificity Validation | Genetic knockdown rescue experiment | BCAT1 siRNA set for off-target compound exclusion |
| Structural Biology | X-ray / Cryo-EM | Key active-site mutant recombinant proteins for co-crystallization screening |
Related Targets for Cross-Selling
- BCAT2: Mitochondrial isoform; mandatory counter-screening target for selectivity. Recommend parallel IC50 determination.
- BCKDK: Branched-chain ketoacid dehydrogenase kinase; downstream negative regulator of BCAA pathway; potential for synthetic lethality or dual pathway blockade with BCAT1 inhibition.
- IDH1: In GBM and AML, IDH mutations interact with BCAT1 metabolic axis; IDH-mutant tumors are highly sensitive to BCAA metabolism disruption, making IDH1 a combination therapy partner.